Cardiovascular Drugs Practice Questions

Q: Which of the following changes in ECG is most commonly associated with Digitalis use?

Prolonged PR interval. ***Prolonged PR interval*** - Digitalis increases **parasympathetic tone** and slows **AV nodal conduction**, leading to a prolonged PR interval [1], [2]. - This effect is often an expected finding and may indicate therapeutic drug levels rather than toxicity, though significant prolongation can be a sign of overdose [1]. *Tall T waves* - **Tall, peaked T waves** are more commonly associated with **hyperkalemia**, a condition that can be exacerbated by digitalis toxicity but is not a direct ECG effect of digitalis itself [3]. - Digitalis typically causes **flattened or inverted T waves** as part of its characteristic "digitalis effect." *ST segment elevation* - **ST segment elevation** is a hallmark sign of **myocardial ischemia or infarction**, indicating acute coronary events. - While digitalis toxicity can cause arrhythmias, it does not directly lead to ST segment elevation. *Prolonged QT interval* - A **prolonged QT interval** is associated with an increased risk of **torsades de pointes** and is a common side effect of many antiarrhythmic drugs and electrolyte imbalances (e.g., hypokalemia, hypomagnesemia). - Digitalis typically causes **shortening of the QT interval** and can predispose to other forms of arrhythmias [1], [4].

Q: Which drug decreases lipoprotein(a) in the blood?

Nicotinic acid (Niacin). ***Nicotinic acid (Niacin)*** - **Nicotinic acid**, particularly at higher doses, is known to significantly **reduce lipoprotein(a) [Lp(a)] levels** in the blood, although the exact mechanism is not fully understood. - This effect is clinically relevant because elevated Lp(a) is an **independent risk factor for cardiovascular disease**. *Statins* - **Statins** are potent inhibitors of **HMG-CoA reductase**, primarily known for reducing **LDL cholesterol** production. - While they are highly effective in lowering LDL-C, statins generally have **minimal or no effect on Lp(a)** levels, and some studies even suggest a potential slight increase. *Ezetimibe* - **Ezetimibe** works by inhibiting the absorption of **dietary and biliary cholesterol** in the small intestine via the **Niemann-Pick C1-Like 1 (NPC1L1) protein**. - Its primary effect is to **lower LDL cholesterol**, and it has **minimal to no impact on Lp(a) levels**. *CETP inhibitors* - **Cholesteryl ester transfer protein (CETP) inhibitors** (e.g., anacetrapib, evacetrapib) were developed to increase **HDL cholesterol** and decrease LDL cholesterol by inhibiting the transfer of cholesteryl esters from HDL to VLDL/LDL. - While they do affect lipoprotein metabolism significantly, they have been shown to have **inconsistent or modest effects on Lp(a)** levels, and their clinical use has been limited due to safety concerns or lack of clinical benefit.

Q: Skin blood flow is decreased by ?

Noradrenaline. ***Noradrenaline*** - **Noradrenaline** (norepinephrine) is a potent **vasoconstrictor**, particularly in the skin, which **decreases blood flow** by stimulating alpha-1 adrenergic receptors. - This vasoconstrictive action redirects blood flow to more vital organs during stress or sympathetic activation. *Dopamine* - At low doses, dopamine can cause **renal and mesenteric vasodilation**, while at higher doses it acts similarly to noradrenaline causing **vasoconstriction**. - Its effects on skin blood flow are variable and dose-dependent; it is not primarily known for consistently decreasing skin blood flow like noradrenaline. *Isoprenaline* - **Isoprenaline** (isoproterenol) is a non-selective **beta-adrenergic agonist** that primarily causes **vasodilation** in most vascular beds, thereby **increasing blood flow**. - It would typically **increase skin blood flow** rather than decrease it, due to its strong beta-2 receptor agonism. *Acetylcholine* - **Acetylcholine** is the primary neurotransmitter for **sympathetic innervation of sweat glands** in the skin, but it also causes **vasodilation** when released by parasympathetic nerves. - In the skin, its overall effect on blood flow is typically **vasodilation**, contributing to heat dissipation.

Q: A patient who is a known case of hypertension on multiple anti-hypertensive medications came to OPD. His ECG finding is given below. Which of the following drugs is responsible for the ECG finding? (Image of ECG finding)

Spironolactone. ***Spironolactone*** - The ECG shows a **tall, peaked T wave**, which is characteristic of **hyperkalemia**. - **Spironolactone** is a **potassium-sparing diuretic**, and its use, especially in combination with other medications or in patients with **renal impairment**, can lead to **hyperkalemia**. *Prazosin* - Prazosin is an **alpha-1 adrenergic blocker** used for **hypertension**. - It does **not directly affect potassium levels** and is not associated with the ECG changes seen in hyperkalemia. *Metoprolol* - Metoprolol is a **beta-blocker** primarily used for **hypertension**, **angina**, and **arrhythmias**. - It does **not significantly cause hyperkalemia** or the characteristic ECG changes shown. *Hydrochlorothiazide* - Hydrochlorothiazide is a **thiazide diuretic** that typically causes **hypokalemia**, not hyperkalemia, by **increasing potassium excretion**. - The ECG findings associated with hypokalemia would include **flattened T waves** or **prominent U waves**.

Q: Which of the following drugs can be given in patients of primary pulmonary hypertension?

Bosentan. ***Bosentan*** - **Bosentan** is an **endothelin receptor antagonist** that blocks the vasoconstrictive and proliferative effects of endothelin-1, a key mediator in the pathogenesis of **pulmonary hypertension**. - It is an FDA-approved medication specifically used for the treatment of **pulmonary arterial hypertension (PAH)**, improving exercise capacity and delaying clinical worsening. *Icatibant* - **Icatibant** is a **bradykinin B2 receptor antagonist** used in the treatment of **hereditary angioedema**. - It has no known role or efficacy in the management of **primary pulmonary hypertension**. *Labetalol* - **Labetalol** is a **beta-blocker** with **alpha-1 adrenergic blocking activity** used primarily for systemic **hypertension** and **hypertensive emergencies**. - Beta-blockers are generally **contraindicated** in pulmonary hypertension as they can worsen right heart function and lead to clinical deterioration. *Sodium nitroprusside* - **Sodium nitroprusside** is a **direct arterial and venous vasodilator** used in hypertensive crises and severe heart failure by reducing both preload and afterload. - While it can lower systemic blood pressure, its use in pulmonary hypertension is **limited** due to the risk of **systemic hypotension** and the lack of selective pulmonary vasodilation compared to other agents.

Q: Endothelin primarily acts through which type of receptors?

Endothelin receptor type A (ETA). ***Endothelin receptor type A (ETA)*** - **ETA receptors** are primarily responsible for the **vasoconstrictive effects** of endothelin-1 in various tissues, leading to increased vascular tone and blood pressure. - Activation of **ETA receptors** on vascular smooth muscle cells mediates signaling pathways that result in **smooth muscle contraction**. *Endothelin receptor type B (ETB)* - **ETB receptors** have dual roles, mediating both **vasoconstriction** (via smooth muscle ETB) and **vasodilation** (via endothelial ETB, stimulating nitric oxide and prostacyclin release). - They also play a significant role in **clearance of endothelin-1** from circulation. *General receptor type (GPCRs)* - While **endothelin receptors (ETA and ETB)** are indeed **G protein-coupled receptors (GPCRs)**, "General receptor type (GPCRs)" is too broad and not the most specific answer for how endothelin *primarily acts*. - Endothelin's specific effects are mediated through its dedicated subtypes of GPCRs, not the general class. *Calcium receptors* - **Calcium receptors** (e.g., calcium-sensing receptors) are involved in sensing extracellular calcium levels and regulating calcium homeostasis. - Endothelin's mechanism involves **intracellular calcium mobilization** *after* receptor activation, but it does not act *through* calcium receptors.

Q: What is the drug of choice for treating tachycardia induced by digitalis?

Phenytoin. ***Phenytoin*** - Phenytoin is the traditional drug of choice for **digitalis-induced tachyarrhythmias** as it blocks **sodium channels**, suppresses **automaticity**, and uniquely improves **AV conduction**. - It effectively counteracts digitalis toxicity by stabilizing the **cardiac membrane** and reducing **ectopic ventricular beats** without worsening conduction abnormalities. *Lidocaine* - Though lidocaine is a **Class IB antiarrhythmic** effective for ventricular arrhythmias, it was not the standard answer for this exam question context. - In modern practice, lidocaine may be preferred due to better **safety profile** and **IV availability**, but phenytoin remains the textbook answer for digitalis toxicity. *Reducing the dosage of digoxin* - While reducing digoxin dosage is important in **chronic management** of digitalis toxicity, it does not provide immediate relief from life-threatening arrhythmias. - This approach is too slow for acute situations requiring prompt **pharmacological intervention** to control dangerous tachycardia. *Verapamil* - Verapamil is **contraindicated** in digitalis toxicity as it can worsen **AV block** and exacerbate the **bradycardia** often associated with digitalis intoxication. - It can also increase **digoxin serum levels** by reducing renal clearance, potentially worsening the toxicity rather than treating it.

Q: What is the primary function of PGI2?

Inhibits platelet aggregation. ***Inhibits platelet aggregation*** - **PGI2 (prostacyclin)** is a potent inhibitor of **platelet aggregation** by increasing cAMP in platelets, preventing thrombus formation. - In the context of **cardiovascular pharmacology** and **hemostasis**, PGI2's antiplatelet action is clinically emphasized as its **primary therapeutic target**, especially when contrasted with **thromboxane A2 (TXA2)**, which promotes platelet aggregation. - PGI2 is often described as the body's **endogenous antiplatelet agent**, making this its most clinically significant function. - It also causes vasodilation (see below), but when discussing PGI2's "primary function" in most pharmacology contexts, the **antiplatelet effect** is highlighted. *Is a vasodilator* - **TRUE but incomplete**: PGI2 is indeed a potent **vasodilator** through smooth muscle relaxation. - However, many substances cause vasodilation, whereas PGI2's unique and clinically defining role in the **COX pathway** is its opposition to platelet aggregation. - Both functions are physiologically important and work synergistically, but in pharmacological classification, the **antiplatelet action** is typically considered the defining characteristic. *Is pyrogenic* - **Incorrect**: PGI2 does not cause fever. - **PGE2** (not PGI2) is the prostaglandin primarily associated with fever induction (pyrogenic effects). *None of the options* - Incorrect because **inhibits platelet aggregation** accurately describes PGI2's primary pharmacological function. - PGI2 has well-established roles in hemostasis and vascular biology.

Q: What type of drug is Sacubitril?

Neutral endopeptidase inhibitor. ***Neutral endopeptidase inhibitor*** - **Sacubitril** is specifically a **neprilysin inhibitor**, which is a type of neutral endopeptidase. - It works by preventing the breakdown of **natriuretic peptides**, leading to vasodilation and natriuresis, beneficial in heart failure. *ACE inhibitor* - **ACE inhibitors** block the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced aldosterone. - While sacubitril is often given in combination with an **angiotensin receptor blocker (valsartan)**, it is not an ACE inhibitor itself. *Calcium channel inhibitor* - **Calcium channel inhibitors** block the influx of calcium into vascular smooth muscle cells and cardiac myocytes, causing vasodilation and reduced myocardial contractility. - This is a distinct mechanism of action from sacubitril, which affects peptide degradation. *Beta adrenergic blocker* - **Beta-adrenergic blockers** inhibit the effects of catecholamines on beta-adrenergic receptors, reducing heart rate and myocardial contractility. - They are used in various cardiovascular conditions but operate through a different pathway than sacubitril.

Question 1

Which of the following changes in ECG is most commonly associated with Digitalis use?

Accepted Answer

Prolonged PR interval

Answer

Tall T waves

Answer

ST segment elevation

Answer

Prolonged QT interval

Question 2

Which drug decreases lipoprotein(a) in the blood?

Accepted Answer

Nicotinic acid (Niacin)

Answer

Statins

Answer

Ezetimibe

Answer

CETP inhibitors

Question 3

Skin blood flow is decreased by ?

Accepted Answer

Noradrenaline

Answer

Isoprenaline

Answer

Dopamine

Answer

Acetylcholine

Question 4

A patient who is a known case of hypertension on multiple anti-hypertensive medications came to OPD. His ECG finding is given below. Which of the following drugs is responsible for the ECG finding? (Image of ECG finding)

Accepted Answer

Spironolactone

Answer

Prazosin

Answer

Metoprolol

Answer

Hydrochlorothiazide

Question 5

What is the primary mechanism of action of beta-blockers in the management of hypertension?

Accepted Answer

Decreasing heart rate and contractility to reduce cardiac output.

Answer

Direct relaxation of vascular smooth muscle.

Answer

Vasodilation through alpha-adrenergic blockade.

Answer

Inhibition of the renin-angiotensin-aldosterone system (RAAS).

Question 6

Which of the following drugs can be given in patients of primary pulmonary hypertension?

Accepted Answer

Bosentan

Answer

Icatibant

Answer

Sodium nitroprusside

Answer

Labetalol

Question 7

Endothelin primarily acts through which type of receptors?

Accepted Answer

Endothelin receptor type A (ETA)

Answer

Calcium receptors

Answer

General receptor type (GPCRs)

Answer

Endothelin receptor type B (ETB)

Question 8

What is the drug of choice for treating tachycardia induced by digitalis?

Accepted Answer

Phenytoin

Answer

Lidocaine

Answer

Reducing the dosage of digoxin

Answer

Verapamil

Question 9

What is the primary function of PGI2?

Accepted Answer

Inhibits platelet aggregation

Answer

Is a vasodilator

Answer

Is pyrogenic

Answer

None of the options

Question 10

What type of drug is Sacubitril?

Accepted Answer

Neutral endopeptidase inhibitor

Answer

ACE inhibitor

Answer

Calcium channel inhibitor

Answer

Beta adrenergic blocker

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?